ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions which will be held June 25-29, 2021, as a virtual event. Topline results of this positive study were shared in a press release distributed on September 15, 2020. In this oral presentation, Gregory Meiffren, Clinical Development Director at Adocia will present
On Tuesday, May 18, Thomas Cochet, Head of Chemical Processes, presented the Quality by Design (QbD)/Design of Experiments (DoE) approach in the context of ADOCIA’s chemical process development. An example with the JMP software! How can the use of experimental designs be used to predict the impact of process parameters on the synthesis of an
This month of April is marked by the release of the 2020 vintage of the Universal Registration Document!This document summarizes the company’s history and the major events that have marked the last 15 years. It provides all the necessary information on Adocia’s activity, scientific results, financial situation, financial results and governance. It is a communication
Lyon, France, September 7th, 2020 – 6:00 pm CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that CEO, Gérard Soula, will present a company overview at the H.C. Wainwright 22nd Annual
Adocia to Present Results of the 1st Phase Ib Study of M1Pram (ADO09) at the Annual Congress of the Société Francophone du Diabète (SFD) Adocia will deliver an oral presentation on the 1st Phase Ib Study of M1Pram (ADO09) (pramlintide insulin) at the Annual Congress of the Société Francophone du Diabète. The data were previously
👉 The INPI France patent list filed 2019 ranks Adocia in 4th place among French SMEs thanks to its 11 patents. Among the top 10 French SMEs, 4 are based in the Auvergne-Rhône-Alpes region. This annual ranking classifies companies by region and size. It has become a reference, highlighting the innovation effort made by the
Last November 14th, Thierry de Catheu and Alessandra Fra invited Adocia to be a guest speaker at the Biotech Agora Event in Paris. We warmly thank Thierry De Catheu and Alssandra Fra and all our shareholders who shared this moment with us! Find an extract of vidéo (French only) To read the Adocia Presentation proposed
Adocia-Analyse Department
In France, more than 3.5 million people live with diabetes. Eve-Marie, a person with type 1 diabetes, dreams of an insulin delivery system that could automatically manage her blood glucose. Part of the answer to that hope may lie in Adocia’s ultra-rapid insulin, which faster action, combined with better algorithms, could significantly improve daily diabetes
Gérard Soula, Adocia CEO
On World Diabetes Day, BFM TV highlighted “the everyday life” of a person with type 1 diabetes (PWD). Taking insulin at mealtime, or even after, is crucial for PWD because it allows marked improvement in the accuracy of the insulin dosage and the person’s quality of life. Gérard Soula, CEO of Adocia, explains how BioChaperone
This October 14th, Gérard Soula, Adocia CEO was interviewed following the Press Release: Adocia obtains additional financial resources to accelerate its growth. To watch the video produced by Didier Testot on the French Web TV: www.labourseetlavie.com